InvestorsHub Logo
Followers 2
Posts 379
Boards Moderated 0
Alias Born 12/04/2016

Re: None

Wednesday, 06/14/2017 11:34:05 PM

Wednesday, June 14, 2017 11:34:05 PM

Post# of 2099
The company already know their drug is an immunotherapy drug and has nothing to do with antiangiogenesis this is why the next trials will be combinations with other immunotherapy drugs and monotherapy . By the way and it's a big by the way if u give vb111 right after surgery that the tumor is small before radiation that suppress immune response together with drops of vb111 at surgery itself on tumor u will get many more cases of cancer cure
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VBLT News